Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 2Active not recruiting 2

Sponsor Class

OTHER 4

Study Type

Observational 7Interventional 4

Sponsor

Cancer Type

Gastrointestinal 82Breast 63Thoracic 53Gynecologic 42Genitourinary 38Lymphoid 32Other hematologic neoplasm 31CNS 31Tumor-Agnostic 28Dermatologic 25Head & Neck 22Sarcoma 20Plasma cell 15Myeloid 9Other solid neoplasm 5Endocrine 4NET 2Classical hematology 1

Conditions

Pituitary Neoplasms 1Neuroendocrine Tumors 1Midgut Neuroendocrine Tumors 1High Grade Neuroendocrine Neoplasms 1Brain Neoplasms 1

Interventions

Everolimus 59lutetium Lu 177 dotatate 46Magnetic Resonance Spectroscopy 33pembrolizumab 31Temozolomide 31Cisplatin 29Nivolumab 26Octreotide 24lanreotide 23cabozantinib 22pasireotide 21gallium Ga 68 dotatate 21lenvatinib 20Etoposide 19Specimen Handling 18Paclitaxel 18Carboplatin 18Capecitabine 18Sunitinib 17Bevacizumab 16trametinib 15dabrafenib 15Doxorubicin 143-Iodobenzylguanidine 14surufatinib 13Sorafenib 13Ipilimumab 13Thyrotropin Alfa 12Injections 12Positron Emission Tomography Computed Tomography 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × Blood Specimen Collection × Endocrine × Clear all
NCT03465618 2026-05-01

A First in Human Study Using 89Zr-cRGDY Ultrasmall Silica Particle Tracers for Malignant Brain Tumors

Memorial Sloan Kettering Cancer Center

Phase 1 Active not recruiting
17 enrolled
CNSEndocrine

Brain Neoplasms, Pituitary Neoplasms

NCT04412629 2026-04-06

Cabozantinib in High Grade Neuroendocrine Neoplasms

Washington University School of Medicine

Phase 2 Active not recruiting
35 enrolled
Endocrine

High Grade Neuroendocrine Neoplasms

NCT03667092 2025-04-10

GENEBIOLuNET

University Hospital, Toulouse

Phase NA Completed
47 enrolled
EndocrineNET

Midgut Neuroendocrine Tumors

NCT02348749 2025-03-19

18F-MFBG Imaging for Evaluation of Neuroendocrine Malignancies

Memorial Sloan Kettering Cancer Center

Phase 1/2 Completed
48 enrolled
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡